Peptide LibraryGlucagon dosage in published studies and labels
These are the doses used for Glucagon in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Glucagon has FDA-approved human dosages for severe low blood sugar in people with diabetes. Injected glucagon is 1 mg for adults and for children weighing 20 kg or more, and 0.5 mg for children under 20 kg, given under the skin, into a muscle or into a vein. Gvoke is 1 mg under the skin from age 12 (0.5 mg for children aged 2 to under 12 who weigh less than 45 kg), and the Baqsimi nasal powder is a single 3 mg dose from age 1. Each label allows one more dose after 15 minutes if there is no response.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous · Intramuscular · Intravenous · Intranasal |
| Frequency | Single emergency dose; one repeat after 15 minutes if there is no response |
| Duration studied | Single use per episode |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Glucagon for Injection, severe hypoglycemiaFDA-approved label · FDA prescribing information | Adults and children with diabetes | 1 mg for adults and children weighing 20 kg or more; 0.5 mg (or 20–30 mcg/kg) for children under 20 kg | Subcutaneous, intramuscular or intravenous (intravenous only under medical supervision) | Once; one more dose after 15 minutes if there is no response | — | Treatment of severe hypoglycemia | Glucagon for Injection (Amphastar) — FDA prescribing information, DailyMed |
| FDA label — Glucagon for Injection, diagnostic aidFDA-approved label · FDA prescribing information | Adults having radiologic examinations | Usually 0.25–0.5 mg intravenously or 1 mg intramuscularly to relax the stomach and small bowel; up to 2 mg if required | Intravenous or intramuscular | Once, before or during the examination | — | Temporary inhibition of gastrointestinal movement | Glucagon for Injection (Amphastar) — FDA prescribing information, DailyMed |
| FDA label — GVOKE, severe hypoglycemiaFDA-approved label · FDA prescribing information | Adults and children aged 2 and over with diabetes | 1 mg from age 12; ages 2 to under 12: 0.5 mg under 45 kg, 1 mg at 45 kg or more | Subcutaneous | Once; one more dose from a new device after 15 minutes if there is no response | — | Treatment of severe hypoglycemia | GVOKE (glucagon injection) — FDA prescribing information, DailyMed |
| FDA label — BAQSIMI nasal powder, severe hypoglycemiaFDA-approved label · FDA prescribing information | Adults and children aged 1 year and older with diabetes | 3 mg as one actuation into one nostril | Intranasal | Once; one more 3 mg dose after 15 minutes if there is no response | — | Treatment of severe hypoglycemia | BAQSIMI (glucagon) nasal powder — FDA prescribing information, DailyMed |
Where sources disagree
- Glucagon is an emergency medicine for severe hypoglycemia and a diagnostic aid for imaging. The labels call for emergency help right after a dose and oral carbohydrate once the person responds.
- Doses are not interchangeable between forms: the nasal powder dose is 3 mg, while injected doses are 0.5 mg or 1 mg.